
Minerva Neurosciences (NERV) Stock Forecast & Price Target
Minerva Neurosciences (NERV) Analyst Ratings
Bulls say
Minerva Neurosciences is poised for success with their potential breakthrough drug, roluperidone, in a market that is projected to be worth $1.9B. Despite regulatory risks and a 65% chance of success, the company has optimized their Phase 3 trial for success and the drug has shown promising results in reducing negative symptoms of schizophrenia and improving cognitive function. While there was a higher than expected loss in the fourth quarter, Minerva has enough funds for their operating plans and the potential for strong sales in the future.
Bears say
Minerva Neurosciences is a clinical-stage biopharmaceutical company with a negative outlook due to the company's unimpressive financial metrics, including a history of losses and uncertainty around future profitability. Additionally, the recent Phase 3 trial for their lead product candidate, Roluperidone, did not meet its primary endpoint and had a high placebo response, raising concerns about its potential efficacy. The company's valuation and stock price may also be affected by clinical trial results, regulatory and approval risks, and the need for additional funding.
This aggregate rating is based on analysts' research of Minerva Neurosciences and is not a guaranteed prediction by Public.com or investment advice.
Minerva Neurosciences (NERV) Analyst Forecast & Price Prediction
Start investing in Minerva Neurosciences (NERV)
Order type
Buy in
Order amount
Est. shares
0 shares